Ozempic vs Mounjaro: Which Is Better for Weight Loss?

"Should I try Ozempic or Mounjaro?" This question comes up constantly in discussions about weight loss in Nigeria. Both medications have transformed how we approach obesity treatment, but they're different products with distinct characteristics. This article provides a straightforward comparison to help you understand your options.

The Fundamental Difference

Ozempic contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly.

Think of it this way: Ozempic activates one key metabolic pathway (GLP-1). Mounjaro activates two pathways simultaneously (GLP-1 and GIP). This dual mechanism is why Mounjaro tends to produce slightly greater weight loss in clinical trials.

Weight Loss Results Compared

Let's look at what the clinical trials actually show:

For a 100kg patient, this difference means:

• Ozempic: Expected loss of approximately 15kg (to 85kg)
• Mounjaro: Expected loss of approximately 21kg (to 79kg)

That 6kg difference is clinically meaningful for many patients, particularly those with very high starting weights or weight-related health conditions. However, 15% weight loss with Ozempic is still substantial and life-changing for most people.

Complete Comparison Table

Side Effects: What's Different?

Both medications cause similar gastrointestinal side effects, but there are some differences in rates:

Mounjaro appears to have lower GI side effect rates despite producing greater weight loss. The GIP component may moderate some of the GLP-1 effects on stomach emptying. For management strategies, see our guide on managing GLP-1 nausea.

Safety and Long-Term Considerations

When choosing between medications, safety track record matters:

Ozempic's Advantages

• 8+ years of post-market data worldwide
• SELECT trial proved cardiovascular risk reduction
• Extensive safety database across millions of patients
• More known about rare side effects and long-term outcomes

Mounjaro's Position

• 4+ years of data; safety profile appears similar to Ozempic
• Cardiovascular outcomes trial still ongoing
• No unexpected safety signals have emerged
• Less long-term experience, but no concerning patterns

For patients with cardiovascular disease or high risk, Ozempic's proven CV benefits may be a deciding factor. For those focused purely on weight loss, both medications appear safe in their current track records.

Practical Considerations for Nigerians

Availability

Neither brand-name product is NAFDAC-registered. However:

• Compounded semaglutide: More widely available from Nigerian providers
• Compounded tirzepatide: Available but from fewer providers
• Both require prescription and medical supervision

Cost Considerations

Pricing varies by provider, but generally:

• Semaglutide tends to be less expensive than tirzepatide
• Higher tirzepatide doses (10-15mg) cost more than lower doses
• Both represent significant ongoing costs that should factor into your decision

For detailed access information, see our guide on how to access GLP-1 medications in Nigeria.

Making Your Decision

Choose Ozempic If:

• You want a medication with a proven long-term track record
• You have cardiovascular disease or high CV risk
• Cost is a significant factor in your decision
• Availability in Nigeria favors semaglutide
• 15% average weight loss would meet your goals

Choose Mounjaro If:

• Maximum weight loss is your priority
• You're comfortable with a newer medication
• You tried semaglutide but plateaued
• Lower GI side effect rates appeal to you
• Your starting weight is very high (BMI 40+)

The Bottom Line

Mounjaro produces greater average weight loss than Ozempic (approximately 21% vs 15%). However, Ozempic has a longer track record and proven cardiovascular benefits that Mounjaro hasn't yet demonstrated.

Both are excellent medications that have helped millions of people achieve significant weight loss. The "best" choice depends on your individual health profile, goals, access, and comfort level with medication history.

For many Nigerian patients, the practical choice may come down to what's available and affordable rather than theoretical differences in efficacy. A medication you can actually access and use consistently will always outperform one you can't obtain.